Supercharge Your Innovation With Domain-Expert AI Agents!

Method for combining desmopressin and M3 receptor antagonist, and composition

A technology of desmopressin and receptor antagonists, which is applied in the field of methods and compositions, can solve problems such as not giving further prompts, and achieve excellent dissolution rate, obvious therapeutic effect, and high safety effect

Inactive Publication Date: 2020-12-18
清远市人民医院
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The combination of desmopressin and M3 receptor antagonist exerts its medicinal effect on the treatment of nocturia, frequent urination, urgency and other lower urinary tract dysfunction, so how to combine the two is the focus of the research of the present invention; How to obtain a better dissolution rate and improve the stability of the drug combination through a suitable prescription and process, the prior art does not give further hints, in view of this, this invention is proposed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for combining desmopressin and M3 receptor antagonist, and composition
  • Method for combining desmopressin and M3 receptor antagonist, and composition
  • Method for combining desmopressin and M3 receptor antagonist, and composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The composition comprising desmopressin and M3 receptor antagonist of this embodiment, the composition comprises the following raw materials in parts by weight:

[0023] 12 parts of desmopressin, 5 parts of M3 receptor antagonist, 1 part of disintegrant, 4 parts of solvent, and 1 part of adhesive.

[0024] The disintegrating agent in this embodiment is a mixture of dioctyl potassium sulfosuccinate and sucrose fatty acid ester in a weight ratio of 1:2.

[0025] The solvent in this example is a mixture of diglycidyl ether and methyl acrylate in a weight ratio of 1:2.

[0026] The binder in this embodiment is hydroxymethyl cellulose.

[0027] A method of combining a composition comprising desmopressin and an M3 receptor antagonist in this embodiment comprises the following steps: pulverizing desmopressin and the M3 receptor antagonist through a 60-mesh sieve, and then crushing the Finally, the material, disintegrant, and solvent are mixed once until they are completely d...

Embodiment 2

[0031] The composition comprising desmopressin and M3 receptor antagonist of this embodiment, the composition comprises the following raw materials in parts by weight:

[0032] 18 parts of desmopressin, 10 parts of M3 receptor antagonist, 5 parts of disintegrant, 10 parts of solvent, and 3 parts of adhesive.

[0033] The disintegrating agent in this embodiment is a mixture of dioctyl potassium sulfosuccinate and sucrose fatty acid ester in a weight ratio of 7:3.

[0034] The solvent in this embodiment is a mixture of diglycidyl ether and methyl acrylate in a weight ratio of 2:1.

[0035] The binder in this embodiment is hydroxymethyl cellulose.

[0036] A method of combining a composition comprising desmopressin and an M3 receptor antagonist in this embodiment comprises the following steps: pulverize desmopressin and the M3 receptor antagonist and pass through a 100-mesh sieve, and then crush the Finally, the material, disintegrant, and solvent are mixed once until they are ...

Embodiment 3

[0040] The composition comprising desmopressin and M3 receptor antagonist of this embodiment, the composition comprises the following raw materials in parts by weight:

[0041] 15 parts of desmopressin, 7.5 parts of M3 receptor antagonist, 3 parts of disintegrant, 7 parts of solvent, and 2 parts of adhesive.

[0042] The disintegrating agent in this embodiment is a mixture of dioctyl potassium sulfosuccinate and sucrose fatty acid ester in a weight ratio of 5:3.

[0043] The solvent in this embodiment is a mixture of diglycidyl ether and methyl acrylate in a weight ratio of 7:2.

[0044] The binder in this embodiment is hydroxymethyl cellulose.

[0045] A method of combining a composition comprising desmopressin and an M3 receptor antagonist in this embodiment comprises the following steps: pulverize desmopressin and the M3 receptor antagonist and pass through an 80-mesh sieve, and then crush the Finally, the material, disintegrant, and solvent are mixed once until they are ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition containing desmopressin and an M3 receptor antagonist. The composition is prepared from the following raw materials in parts by weight: 12 to 18 parts of the desmopressin, 5 to 10 parts of the M3 receptor antagonist, 15 parts of a disintegrating agent, 4 to 10 parts of a solvent and 1 to 3 parts of an adhesive. The composition containing the desmopressin and the M3 receptor antagonist is formed by combining the desmopressin, the M3 receptor antagonist, the disintegrating agent, the solvent and the adhesive; through the addition of the disintegrating agent,the dissolution of medicine can be promoted; the combining effect of the desmopressin and the M3 receptor antagonist is improved; and the proportion of the raw materials and the selection of the rawmaterials have great influence on medicine properties. Tests on the dissolution rate and the fluidity of the medicine properties show that the medicine provided by the invention has the excellent dissolution rate; and meanwhile, stability experiments and the safety experiments show that the product has stable performance and high safety, and achieves an obvious treatment effect on enuresis nocturna.

Description

technical field [0001] The invention relates to the technical field of treatment of frequent urination, urgency and nocturia, and in particular relates to a method and composition comprising a combination of desmopressin and an M3 receptor antagonist. Background technique [0002] Nocturia and other urinary frequency conditions affect a large proportion of humans. Patients with nocturia experience disrupted sleep due to the need to get up during the night to urinate. Patients with overactive bladder often experience urge incontinence, frequent urination. Nocturia, frequent urination, urgency and other lower urinary tract dysfunction seriously affect the quality of work and life. Patients with nocturia often have lower urinary tract symptoms such as frequent urination and urgency. [0003] Desmopressin (1-deamino-8-D-arginine vasopressin, dDAVP) is an analog of vasopressin. Desmopressin acetate is commercially available in tablet and nasal spray forms and is commonly used...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K38/095A61K9/16A61K47/38A61P13/00
CPCA61K45/06A61K38/095A61K9/1652A61P13/00A61K2300/00
Inventor 曾健文朱宝益廖俊豪李伟健麦俊彦陈告煌冯振宇古晋鹏
Owner 清远市人民医院
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com